Advances in Acute Lymphoblastic Leukemia Treatment
A Special Issue of Cancers (ISSN 2072-6694) belonging to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 January 2027 | Viewed by 1294
Editor
Special Issue Information
Dear Colleagues,
Although Acute Lymphoblastic Leukemia (ALL) is primarily recognized as the most prevalent pediatric malignancy, it presents a significant clinical challenge in the adult population. While pediatric cure rates have reached 90% through standard chemotherapy, adult outcomes remain suboptimal at approximately 50%, largely due to high relapse rates and emergent drug resistance. A definitive consensus on the management of newly diagnosed adults—specifically the elderly—has yet to be established.
The purpose of this Special Issue is to explore diverse treatment options and significant clinical advances made in recent years. We invite submissions of original research articles and comprehensive reviews that contribute to our understanding of this evolving landscape.
Dr. Roberta Buono
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute lymphoblastic leukemia
- biology
- clinical trial
- treatment
- chemotherapy
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
